GLP1R and type 2 diabetes mellitus: For example, randomisation to the glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide 2.4 mg once weekly plus lifestyle intervention resulted in 10-15% weight loss by follow-up at week 68 in patients with overweight or obesity, with or without type 2 diabetes [24, 25].